EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis

Rachel F Rollo iD, Giorgia Mori iD, Timothy A Hill iD, Doris Hillemann, Stefan Niemann iD, Susanne Homolka iD, David P Fairlie iD, Antje Blumenthal iD

Microbiology Spectrum · 17.08.2023 · 11 (4)

DOI: 10.1128/spectrum.00465-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 17.08.2023. Verfasst von Rachel F Rollo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Defense, DHAC | National Health and Medical Research Council, Department of Education and Training | Australian Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) is an infectious disease that affects millions of people globally, with 1.6 million deaths annually. TB treatment requires combinations of multiple different antibiotics for many months, and toxic side effects can occur.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantHumansAntitubercular AgentsEthambutolMicrobial Sensitivity TestsNitroimidazoles

Stichwörter der Autor:innen

Mycobacterium tuberculosisantimicrobial combinationsmultidrug resistance

Substanzen

Antitubercular AgentsEthambutolpretomanidNitroimidazoles

Autor:innen und Institutionen

  • Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia.
  • Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
  • Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
  • National and WHO Supranational Reference Center for Mycobacteria, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
  • Molecular and Experimental Mycobacteriology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
  • German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.

ORCID-Profile: Rachel F Rollo, Giorgia Mori, Timothy A Hill, Stefan Niemann, Susanne Homolka, David P Fairlie, Antje Blumenthal

Förderung

  • U.S. Department of Defense
  • DHAC | National Health and Medical Research Council
  • Department of Education and Training | Australian Research Council

Zitieren

APA

Rollo, R. F., Mori, G., Hill, T. A., Hillemann, D., Niemann, S., Homolka, S., Fairlie, D. P., & Blumenthal, A. (2023). Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis. Microbiology Spectrum, 11(4). https://doi.org/10.1128/spectrum.00465-23

Vancouver

Rollo RF, Mori G, Hill TA, Hillemann D, Niemann S, Homolka S, et al. Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis. Microbiology Spectrum. 2023;11(4). doi:10.1128/spectrum.00465-23

BibTeX
@article{Rollo2023,
  author = {Rollo, Rachel F and Mori, Giorgia and Hill, Timothy A and Hillemann, Doris and Niemann, Stefan and Homolka, Susanne and Fairlie, David P and Blumenthal, Antje},
  title = {Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis},
  journal = {Microbiology Spectrum},
  year = {2023},
  volume = {11},
  number = {4},
  doi = {10.1128/spectrum.00465-23}
}
Kostenlos starten →